| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 2.30 % |
| Fastest Growing 乐鱼体育官网 | Asia Pacific |
| Largest 乐鱼体育官网 | North America |
| 乐鱼体育官网 Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hyperlipidemia Drugs 乐鱼体育官网 Analysis
The Global Hyperlipidemia Drugs 乐鱼体育官网 is expected to register a CAGR of 2.3% during the forecast period.
The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission as most chronic therapies were regarded as non-urgent. However, the intake of hyperlipidemia drugs in COVID-19-affected patients reduced the severity of the infection. According to a report by UC San Diego Health published in July 2021, intake of statin medications had a 41% lower risk of in-hospital death from COVID-19. Also, the report indicated that the use of statins or an anti-hypertension medication was associated with a 32% lower risk of death among COVID-19 in patients with a history of cardiovascular disease or hypertension. Such factors helped in the 乐鱼体育官网 growth during the COVID-19 pandemic.
The hyperlipidemia drug 乐鱼体育官网 is growing at a good rate attributing to an increase in the target population and growth in awareness about risk of cardiovascular diseases (CVD) due to persistent hypercholesterolemia. The American Heart Association in its 2022 update on Heart Disease and Stroke Statistics showed that in 2020, around 19.05 million deaths were reported globally because of cardiovascular diseases.
Several product launches is also anticipated to drive the hyperlipidemia drugs 乐鱼体育官网. For instance, In December 2021, the United States Food and Drug Administration approved Leqvio (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year. Such approvals are likely to aid in the 乐鱼体育官网 growth.
However, the upcoming patent expiration of drugs and the regulatory frameworks are expected to slow down the 乐鱼体育官网 growth over the forecast period.
Hyperlipidemia Drugs 乐鱼体育官网 Trends
Statin Hyperlipidemia Drugs Segment is Expected to witness healthy growth in the Hyperlipidemia Drugs 乐鱼体育官网
Statins are expected to witness a healthy CAGR owing to a surge in the incidence of cardiovascular disorders. Statins are the first line of therapy that reduces the risk associated with heart attacks which also contributes to the growth of the 乐鱼体育官网.
Several clinical trials have been conducted by the 乐鱼体育官网 players on the study of statin treatment for dyslipidemia. For instance, in November 2021, Pfizer announced topline results from the Phase 2b study of vupanorsen (PF-07285557), an investigational antisense therapy being developed for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study showed that vupanorsen achieved a statistically significant lowering of non- HDL-C, triglycerides, and other lipoproteins related to cardiovascular disease.
Also, in September 2022, the University of Pennsylvania started a clinical trial to evaluate the efficiency of statins based on non-visit and visit-based interventions for their optimized referral to patients affected by hyperlipidemia. Such studies which focus on the utilization of statins for the lipid disorders are expected to add to the growth of the 乐鱼体育官网 segment over the forecast period.
Furthermore, benefits such as improved endothelial function enhanced stability of atherosclerotic plaques, and reduce the amount of inflammation and damage done to cells due to oxidative stress are also responsible for preferring statins and driving the 乐鱼体育官网. Moreover, PCSK9 inhibitors are also expected to grow in the forecasted period attributed to a drastic reduction of LDL levels in the blood.
Understand The Key Trends Shaping This 乐鱼体育官网
Download PDF
North America is Expected to Hold a Significant Share in the 乐鱼体育官网 and Expected to do Same in the Forecast Period
North America is expected to hold a major 乐鱼体育官网 share in the global Hyperlipidemia Drugs 乐鱼体育官网 due to the increasing prevalence of hypercholesteremia, increasing healthcare expenditure, and the presence of a well-established healthcare infrastructure.
Moreover, the surge in the obese population in this region leading to adoption of hyperlipidemia drugs for diagnostic purposes is also anticipated to contribute to promoting 乐鱼体育官网 growth. For instance, according to the Adult Obesity Facts by the Centers for Disease Control and Prevention (CDC) updated in May 2022, in the United States, in 2018, the prevalence of obesity was found to be 42.4%. From 2000 through 2018, the United States obesity prevalence increased from 30.5% to 42.4%. During the same period, the prevalence of severe obesity increased from 4.7% to 9.2%. Thus, such a high burden of obesity among the United States population is likely to drive 乐鱼体育官网 growth.
As per the above-mentioned report, one in five children and adolescents are affected by overweight and obesity problems. The report indicated that the prevalence of obesity was 19.7% and affected about 14.7 million children and adolescents.
Also, the increasing healthcare expenditure in the United States is expected to drive the demand for the 乐鱼体育官网 in this region. According to the United States Centers for Medicare & Medicaid Services National Health Expenditure Data 2020, healthcare expenditure grew from 9.7% to USD 4.1 trillion in 2020 and accounted for around 19.7% of the Gross Domestic Product. The expenditure is projected to reach USD 6.2 trillion by 2028. The rise in the healthcare expenditure in the United States region is likely to boost the growth of the 乐鱼体育官网 over the forecast period of the study.
The recent product approvals also aid in the 乐鱼体育官网 growth. For instance, in April 2021, the Food and Drug Administration had approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol. Such activities are expected to boost the 乐鱼体育官网 growth over the forecast period.
Get Analysis on Important Geographic 乐鱼体育官网s
Download PDF
Hyperlipidemia Drugs Industry Overview
The hyperlipidemia drugs 乐鱼体育官网 is fragmented competitive and consists of several major players. In terms of 乐鱼体育官网 share, few of the major players are currently dominating the 乐鱼体育官网. Some of the companies which are currently dominating the 乐鱼体育官网 are Dr. Reddy's Laboratories, Viatris Inc., Amgen, Sanofi, AstraZeneca, Merck & Co., Inc, and DAIICHI SANKYO COMPANY, LIMITED.
Hyperlipidemia Drugs 乐鱼体育官网 Leaders
-
Merck & Co., Inc
-
Sanofi
-
Amgen
-
AstraZeneca
-
Viatris Inc.
- *Disclaimer: Major Players sorted in no particular order
Need More Details on 乐鱼体育官网 Players and Competiters?
Download PDF
Hyperlipidemia Drugs 乐鱼体育官网 News
- In August 2022, Esperion indicated that bempedoic acid (NEXLETOL) was recommended as an important oral non-statin therapy for LDL-cholesterol (LDL-C) lowering in the management of atherosclerotic cardiovascular disease (ASCVD) by the American College of Cardiology (ACC) task force on expert consensus decision pathways (ECDP).
- In May 2022, Zydus Lifesciences launched its Bempedoic acid drug in India under the Bemdac brand for the treatment of uncontrolled levels of bad cholesterol.
Hyperlipidemia Drugs Industry Segmentation
As per the scope of this report, hyperlipidemia is a condition that is caused by abnormally high lipid levels in the blood and it is the most common type of dyslipidemia. This disorder can happen due to genetic factors (primary hyperlipidemia) as well as other factors such as unhealthy lifestyle and poor diet (secondary hyperlipidemia). Statins are the first line of treatment for secondary hyperlipidemia. The hyperlipidemia 乐鱼体育官网 is segmented by drug class (statins, cholesterol absorption inhibitors, bile acid sequestrants, pcsk9 inhibitors, others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The 乐鱼体育官网 report also covers the estimated 乐鱼体育官网 sizes and trends of 17 countries across major regions globally. The report offers the value in USD million for the above segments.
| By Drug Class | Statins | ||
| Cholesterol Absorption Inhibitors | |||
| Bile Acid Sequestrants | |||
| PCSK9 Inhibitors | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle-East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle-East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Hyperlipidemia Drugs 乐鱼体育官网 Research FAQs
What is the current Global Hyperlipidemia Drugs 乐鱼体育官网 size?
The Global Hyperlipidemia Drugs 乐鱼体育官网 is projected to register a CAGR of 2.3% during the forecast period (2025-2030)
Who are the key players in Global Hyperlipidemia Drugs 乐鱼体育官网?
Merck & Co., Inc, Sanofi, Amgen, AstraZeneca and Viatris Inc. are the major companies operating in the Global Hyperlipidemia Drugs 乐鱼体育官网.
Which is the fastest growing region in Global Hyperlipidemia Drugs 乐鱼体育官网?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Hyperlipidemia Drugs 乐鱼体育官网?
In 2025, the North America accounts for the largest 乐鱼体育官网 share in Global Hyperlipidemia Drugs 乐鱼体育官网.
What years does this Global Hyperlipidemia Drugs 乐鱼体育官网 cover?
The report covers the Global Hyperlipidemia Drugs 乐鱼体育官网 historical 乐鱼体育官网 size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Hyperlipidemia Drugs 乐鱼体育官网 size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Netherlands Aesthetic Device Industry Report
Statistics for the 2025 Global Hyperlipidemia Drugs 乐鱼体育官网 share, size and revenue growth rate, created by Mordor Intelligence鈩� Industry Reports. Global Hyperlipidemia Drugs analysis includes a 乐鱼体育官网 forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
